Latest Hotspot

Crestone Releases Encouraging Phase 2 Trial Results for CRS3123 in Treating C. Difficile Infections (CDI)

9 September 2024
3 min read

Crestone, Inc. ("Crestone") announced promising initial results from its Phase 2 clinical trial of CRS3123 in patients with Clostridioides difficile infection (CDI). CRS3123, a novel therapeutic agent, demonstrated limited spectrum activity and negligible effects on normal gut microbiota in preclinical and Phase 1 studies. The primary intent-to-treat (ITT) analysis encompassed 43 patients, showing consistent clinical cure rates at the day 12 test-of-cure visit across all three treatment groups. Specifically, 28 out of 29 patients (97%) administered either of the two dosages of CRS3123 achieved clinical cure, in comparison to 13 out of 14 patients (93%) receiving vancomycin. No instances of clinical failure were noted at the day 12 evaluation, although results for two patients remained inconclusive.

👇Discover comprehensive information about this drug, from its R&D status, core patents, clinical trials to approval status in global countries, by simply clicking on the image below. Dive deep into our drug database now.

图形用户界面, 应用程序

描述已自动生成

Noticeably, patients receiving CRS3123 experienced a substantial drop in CDI recurrence rates. For example, by the 40th day, the recurrence rate was 4% for CRS3123 compared to 23% for vancomycin. CRS3123's tolerability was high, with no significant adverse events linked to the treatment. Crestone plans to showcase the Phase 2 trial outcomes at a forthcoming medical conference.

CDI remains the most prevalent hospital-acquired infection in the United States and has increasingly spread within the community, even impacting younger demographics. The U.S. records almost half a million cases per year, with approximately 30,000 related fatalities.

Dr. Thomas Louie of the University of Calgary in Canada, who led the research, stated: “Tackling C. difficile infection urgently requires therapies that maintain gut microbiota, aiding in microbiome recovery and preventing recurrent CDI. The results from this study suggest that CRS3123 is a favorable candidate for further investigation.”

The study’s epidemiological analysis and toxin assays were performed at the University of Leeds. Dr. Mark Wilcox, a professor at Leeds Teaching Hospitals and the University of Leeds, as well as the CDI Lead for the UK Health Security Agency, noted: “Effectively addressing C. difficile while sustaining healthy gut flora is the aim of CDI therapies. This Phase 2 study’s findings support that goal.”

Dr. Jon Bruss, Interim Chief Medical Officer at Crestone, commented: “We are thrilled with these results. Conducting this study was tough due to the pandemic’s strain on healthcare systems. We profoundly appreciate the contributions of the patients, their families, the clinicians, and our partners to these essential data.”

👇Explore the latest research progress on drug-related developments, indications, therapeutic organizations, clinical trials, results, and patents by clicking on the targeted picture link below. Unfold a world of comprehensive information on this target in just a click!

图形用户界面, 文本, 应用程序

描述已自动生成

According to the data provided by the Synapse Database, As of September 9, 2024, there are 3 investigational drug for the MetRS targets, including 5 indications, 6 R&D institutions involved, with related clinical trials reaching 3, and as many as 331 patents.

CRS-3123 is a small molecule drug that targets MetRS and falls under the therapeutic area of Infectious Diseases, specifically active against Clostridium difficile infection. The originator organization of this drug is the National Institute of Allergy & Infectious Diseases. As of now, CRS-3123 has reached the highest phase of development globally, which is Phase 2.

图形用户界面, 文本, 应用程序

描述已自动生成

Aurinia Reports Initial Participant Dosed in AUR200 Single-Dose Trial
Latest Hotspot
3 min read
Aurinia Reports Initial Participant Dosed in AUR200 Single-Dose Trial
9 September 2024
Aurinia Pharmaceuticals recently disclosed that the first participant has received the initial dose in a Phase 1a single ascending dose (SAD) clinical trial for AUR200.
Read →
Fenebrutinib by Roche Significantly Reduces Disease Activity and Disability Progression in Relapsing Multiple Sclerosis Over 48 Weeks
Latest Hotspot
3 min read
Fenebrutinib by Roche Significantly Reduces Disease Activity and Disability Progression in Relapsing Multiple Sclerosis Over 48 Weeks
9 September 2024
Roche's fenebrutinib showed almost total reduction in disease activity and disability advancement for as long as 48 weeks in patients with relapsing multiple sclerosis.
Read →
Invivyd Initiates Phase 1 Trial of New COVID-19 Monoclonal Antibody VYD2311, Building on PEMGARDA™ Success
Latest Hotspot
3 min read
Invivyd Initiates Phase 1 Trial of New COVID-19 Monoclonal Antibody VYD2311, Building on PEMGARDA™ Success
9 September 2024
Invivyd starts initial dosing in Phase 1 trial of VYD2311, a new monoclonal antibody for COVID-19, expanding on PEMGARDA™'s success.
Read →
Biogen Announces Promising Results for Higher-Dose Nusinersen in SMA Therapy
Latest Hotspot
4 min read
Biogen Announces Promising Results for Higher-Dose Nusinersen in SMA Therapy
9 September 2024
Biogen Reports Encouraging Topline Results from Study on Higher Dose of Nusinersen, Demonstrating Notable Success in SMA Treatment.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.